- Home
- CYH vs PSNL Comparison
CYH vs PSNL Comparison
Compare CYH & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- PSNL
- Stock Information
- Founded
- CYH 1985
- PSNL 2011
- Country
- CYH United States
- PSNL United States
- Employees
- CYH 61000
- PSNL N/A
- Industry
- CYH Hospital/Nursing Management
- PSNL Medical Specialities
- Sector
- CYH Health Care
- PSNL Health Care
- Exchange
- CYH Nasdaq
- PSNL Nasdaq
- Market Cap
- CYH 487.7M
- PSNL 460.7M
- IPO Year
- CYH 1991
- PSNL 2019
- Fundamental
- Price
- CYH $3.52
- PSNL $4.72
- Analyst Decision
- CYH Hold
- PSNL Strong Buy
- Analyst Count
- CYH 7
- PSNL 4
- Target Price
- CYH $4.18
- PSNL $7.81
- AVG Volume (30 Days)
- CYH 2.8M
- PSNL 1.0M
- Earning Date
- CYH 02-18-2025
- PSNL 02-27-2025
- Dividend Yield
- CYH N/A
- PSNL N/A
- EPS Growth
- CYH N/A
- PSNL N/A
- EPS
- CYH N/A
- PSNL N/A
- Revenue
- CYH $12,634,000,000.00
- PSNL $87,489,000.00
- Revenue This Year
- CYH $1.23
- PSNL $16.00
- Revenue Next Year
- CYH $1.75
- PSNL $1.29
- P/E Ratio
- CYH N/A
- PSNL N/A
- Revenue Growth
- CYH 1.15
- PSNL 24.05
- 52 Week Low
- CYH $2.60
- PSNL $1.14
- 52 Week High
- CYH $6.29
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- CYH 57.57
- PSNL 43.46
- Support Level
- CYH $3.11
- PSNL $4.47
- Resistance Level
- CYH $3.79
- PSNL $6.43
- Average True Range (ATR)
- CYH 0.22
- PSNL 0.51
- MACD
- CYH 0.02
- PSNL 0.00
- Stochastic Oscillator
- CYH 62.84
- PSNL 12.50
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.